Natco Pharma rises on launching Brivaracetam tablets in India
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Natco Pharma is currently trading at Rs. 807.05, up by 4.85 points or 0.60% from its previous closing of Rs. 802.20 on the BSE.
The scrip opened at Rs. 815.00 and has touched a high and low of Rs. 817.90 and Rs. 795.10 respectively. So far 5037 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 995.05 on 28-Sep-2020 and a 52 week low of Rs. 450.00 on 25-Mar-2020.
Last one week high and low of the scrip stood at Rs. 835.00 and Rs. 788.00 respectively. The current market cap of the company is Rs. 14715.57 crore.
The promoters holding in the company stood at 48.91%, while Institutions and Non-Institutions held 33.21% and 17.88% respectively.
Natco Pharma has launched Brivaracetam tablets under brand Brecita in India. Brivaracetam is indicated towards treatment of epilepsy. Brivaracetam is developed by UCB Pharma and currently marketed in India by Dr Reddy’s under brand name Briviact. Natco’s Brecita tablets will be available in two strengths of 50mg and 100mg at significantly lower MRP prices of Rs 25 and Rs 35 per tablet respectively.
Epilepsy patients in India is estimated to be between 5-10 million, as per GEMIND guidelines.
Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.
